combination therapy

1:56
Effective antibody therapy and updates from the POLLUX and CASTER trials at IMW
Meletios Dimopoulos
5:23
The risk of skeletal adverse events with zoledronic acid
Heinz Ludwig
1:41
New trials in relapsed high-grade lymphomas
Graham Collins
6:13
What is the best treatment regimen for MM?
Laurent Garderet
1:45
Isatuximab and pomalidomide for the treatment of MM
Joseph R. Mikhael
2:38
Venetoclax in combination with low-dose cytarabine – a promising regimen for the treatment of AML
Andrew Wei
1:32
Is venetoclax in combination with low-dose cytarabine a safe regimen for the treatment of AML?
Andrew Wei
3:22
Promising CLL & FL data from ICML 2017: BGB-3111 and obinituzumab
Susan O’Brien
4:09
Tackling unmet needs in lymphoma
Graham Collins
3:47
What is the potential of daratumumab in combination therapy for myeloma?
Torben Plesner
8:08
Evolving CLL treatments: creating choices and igniting discussions
Deborah Henderson et al.
1:28
Achieving deep responses in previously treated CLL patients
Danielle Brander
0:55
Do we need to stratify follicular lymphoma (FL) patients for treatment?
Jessica Okosun
1:49
What are the benefits of having different chronic lymphocytic leukemia (CLL) treatment options?
Barbara Eichhorst
1:37
Which is the best combination therapy in relapsed and refractory multiple myeloma?
Meletios Dimopoulos
2:08
What do current multiple myeloma clinical trials have in common?
Xavier Leleu
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals